View ValuationRedcare Pharmacy 향후 성장Future 기준 점검 4/6Redcare Pharmacy (는) 각각 연간 55.4% 및 10.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 55.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.5% 로 예상됩니다.핵심 정보55.4%이익 성장률55.92%EPS 성장률Consumer Retailing 이익 성장10.0%매출 성장률10.5%향후 자기자본이익률12.46%애널리스트 커버리지Good마지막 업데이트08 May 2026최근 향후 성장 업데이트Price Target Changed • Jan 07Price target decreased by 7.5% to €140Down from €151, the current price target is an average from 8 analysts. New target price is 107% above last closing price of €67.40. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €1.18 next year compared to a net loss per share of €2.27 last year.공시 • Mar 13Redcare Pharmacy NV Provides Earnings Guidance for 2025Redcare Pharmacy NV provided earnings guidance for 2025. The company expects Total sales growth in excess of 25%.Breakeven Date Change • Dec 30Forecast breakeven date pushed back to 2026The 12 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 40% per year to 2025. The company is expected to make a profit of €55.9m in 2026. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Breakeven Date Change • Oct 28Forecast to breakeven in 2025The 12 analysts covering Redcare Pharmacy expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €10.2m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.공시 • Oct 04Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024Redcare Pharmacy NV revised sales guidance for the full year 2024. The company expected for the full year 2024 that sales will end up slightly higher than predicted at the start of the year, and new guidance is total sales between EUR 2.35 billion and EUR 2.5 billion.Breakeven Date Change • Mar 07Forecast breakeven date moved forward to 2024The 10 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €7.15m in 2024. Earnings growth of 61% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates공시 • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.공시 • Feb 07Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026공시 • Jan 28Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft SpecificationsRedcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition.공시 • Jan 08Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026Price Target Changed • Jan 07Price target decreased by 7.5% to €140Down from €151, the current price target is an average from 8 analysts. New target price is 107% above last closing price of €67.40. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €1.18 next year compared to a net loss per share of €2.27 last year.공시 • Nov 12+ 1 more updateRedcare Pharmacy NV Designates Hendrik Krampe as Chief Financial Officer, Effective 1 December 2025Redcare Pharmacy announced that the Supervisory Board has designated Hendrik Krampe as Chief Financial Officer, effective 1 December 2025. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. Hendrik Krampe has twenty years of experience in the financial management of fast growing e-commerce businesses. Since 2014, he worked at Amazon where he held the role of Finance Director of the European marketplace business for the last eight years. From 2004 to 2014, Hendrik was at eBay in Germany as well as in the US in various roles including Finance Director of eBay’s Retail Media business. His broad expertise in efficiently scaling digital businesses, particularly marketplaces and Retail Media, complements Redcare Pharmacy´s strategy and will strengthen its core Rx and OTC business. The planned appointment of Hendrik comes at a time of continued growth momentum following strong third quarter results. It will support the company’s aim to increasingly capture economies of scale and improve profitability.공시 • Oct 07Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025공시 • Sep 28Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management BoardRedcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor.공시 • Mar 19Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025공시 • Mar 13Redcare Pharmacy NV Provides Earnings Guidance for 2025Redcare Pharmacy NV provided earnings guidance for 2025. The company expects Total sales growth in excess of 25%.공시 • Mar 11Redcare Pharmacy NV to Report Q1, 2025 Results on May 06, 2025Redcare Pharmacy NV announced that they will report Q1, 2025 results on May 06, 2025공시 • Jan 09Redcare Pharmacy NV to Report Fiscal Year 2024 Final Results on Mar 11, 2025Redcare Pharmacy NV announced that they will report fiscal year 2024 final results on Mar 11, 2025Breakeven Date Change • Dec 30Forecast breakeven date pushed back to 2026The 12 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 40% per year to 2025. The company is expected to make a profit of €55.9m in 2026. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Reported Earnings • Nov 10Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €574.5m (up 21% from 3Q 2023). Net loss: €6.91m (down 183% from profit in 3Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe.Breakeven Date Change • Oct 28Forecast to breakeven in 2025The 12 analysts covering Redcare Pharmacy expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €10.2m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.공시 • Oct 04Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024Redcare Pharmacy NV revised sales guidance for the full year 2024. The company expected for the full year 2024 that sales will end up slightly higher than predicted at the start of the year, and new guidance is total sales between EUR 2.35 billion and EUR 2.5 billion.Reported Earnings • Jul 31Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €560.7m (up 34% from 2Q 2023). Net loss: €4.27m (loss narrowed 6.4% from 2Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in Europe.공시 • Jul 30Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year. Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year.New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding).Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: €560.2m (up 51% from 1Q 2023). Net loss: €7.81m (loss narrowed 24% from 1Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe.공시 • Mar 07Redcare Pharmacy NV Announces Management DeparturesThe Supervisory Board of Redcare Pharmacy NV agreed to the early departure request of the Managing Board members Stephan Weber (CCO) and Marc Fischer (CIO) at the Annual General Meeting on 17 April 2024. This decision comes at an ideal time to transition leadership responsibilities approximately one year before the end of their regular terms of office. This succession plan had been carefully developed and is the result of an extensive evaluation and selection process. Both Stephan Weber and Marc Fischer have agreed with the Supervisory Board to serve Redcare Pharmacy in an advisory capacity until October 2026, provided the relevant agenda item is approved by the Annual General Meeting.New Risk • Mar 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.Breakeven Date Change • Mar 07Forecast breakeven date moved forward to 2024The 10 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €7.15m in 2024. Earnings growth of 61% is required to achieve expected profit on schedule.공시 • Mar 06+ 2 more updatesRedcare Pharmacy NV to Report Q3, 2024 Results on Nov 05, 2024Redcare Pharmacy NV announced that they will report Q3, 2024 results on Nov 05, 2024Reported Earnings • Mar 06Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: €0.73 loss per share (improved from €4.32 loss in FY 2022). Revenue: €1.80b (up 49% from FY 2022). Net loss: €12.0m (loss narrowed 85% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.공시 • Mar 05Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024, at 10:00 Central European Standard Time. Agenda: To consider directorate changes.Price Target Changed • Jan 09Price target increased by 7.6% to €142Up from €132, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €140. Stock is up 144% over the past year. The company is forecast to post a net loss per share of €0.86 next year compared to a net loss per share of €4.32 last year.Breakeven Date Change • Nov 10Forecast breakeven date moved forward to 2024The 11 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 76% to 2023. The company is expected to make a profit of €229.6k in 2024. Average annual earnings growth of 64% is required to achieve expected profit on schedule.Reported Earnings • Oct 31Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €475.5m (up 67% from 3Q 2022). Net income: €8.32m (up €28.4m from 3Q 2022). Profit margin: 1.7% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe.Recent Insider Transactions • Aug 11CFO & Member of Management Board recently sold €1.0m worth of stockOn the 7th of August, Jasper F. Eenhorst sold around 9k shares on-market at roughly €112 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jasper F. has been a net seller over the last 12 months, reducing personal holdings by €992k.New Risk • Aug 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Significant insider selling over the past 3 months (€454k sold).Reported Earnings • Aug 02Second quarter 2023 earnings released: €0.24 loss per share (vs €1.37 loss in 2Q 2022)Second quarter 2023 results: €0.24 loss per share (improved from €1.37 loss in 2Q 2022). Revenue: €419.9m (up 46% from 2Q 2022). Net loss: €4.56m (loss narrowed 82% from 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.New Risk • Jun 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €65m Forecast net loss in 2 years: €3.3m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€3.3m net loss in 2 years). Significant insider selling over the past 3 months (€785k sold).Price Target Changed • Jun 08Price target increased by 8.1% to €101Up from €93.00, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €96.06. Stock is up 7.1% over the past year. The company is forecast to post a net loss per share of €1.87 next year compared to a net loss per share of €4.32 last year.Price Target Changed • May 23Price target increased by 7.5% to €99.08Up from €92.17, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €97.98. Stock is up 15% over the past year. The company is forecast to post a net loss per share of €2.97 next year compared to a net loss per share of €4.32 last year.Recent Insider Transactions • May 12Co-Founder recently sold €454k worth of stockOn the 5th of May, Marc Fischer sold around 5k shares on-market at roughly €90.80 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months.Breakeven Date Change • May 05Forecast to breakeven in 2025The 9 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €15.8m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: €0.56 loss per share. Revenue: €372.1m (up 22% from 1Q 2022). Net loss: €10.2m (loss narrowed 55% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Consumer Retailing industry in Europe.Breakeven Date Change • Apr 11Forecast to breakeven in 2025The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.44m in 2025. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Recent Insider Transactions • Apr 05COO & Member of the Managing Board recently sold €331k worth of stockOn the 30th of March, Theresa Holler sold around 4k shares on-market at roughly €78.85 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.4m more than they bought in the last 12 months.Reported Earnings • Mar 09Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: €4.32 loss per share (further deteriorated from €4.15 loss in FY 2021). Revenue: €1.20b (up 14% from FY 2021). Net loss: €77.6m (loss widened 4.7% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Breakeven Date Change • Mar 08No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €26.3m in 2025. New consensus forecast suggests the company will make a loss of €377.1k in 2025.Recent Insider Transactions • Jan 31COO & Member of the Managing Board recently sold €149k worth of stockOn the 24th of January, Theresa Holler sold around 2k shares on-market at roughly €64.72 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Theresa has been a net seller over the last 12 months, reducing personal holdings by €260k.Buying Opportunity • Jan 05Now 22% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be €66.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 40% in 2 years. Earnings is forecast to grow by 78% in the next 2 years.Price Target Changed • Jan 05Price target decreased to €84.43Down from €92.00, the current price target is an average from 14 analysts. New target price is 63% above last closing price of €51.68. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €4.02 next year compared to a net loss per share of €4.15 last year.Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €26.3m in 2025. Average annual earnings growth of 55% is required to achieve expected profit on schedule.Recent Insider Transactions • Dec 22Chairman of the Managing Board & CEO recently bought €85k worth of stockOn the 16th of December, Stefan Feltens bought around 2k shares on-market at roughly €42.58 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.공시 • Dec 20+ 3 more updatesShop Apotheke Europe N.V. to Report Fiscal Year 2022 Results on Mar 07, 2023Shop Apotheke Europe N.V. announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Mar 07, 2023Price Target Changed • Nov 10Price target decreased to €91.64Down from €98.79, the current price target is an average from 14 analysts. New target price is 106% above last closing price of €44.43. Stock is down 70% over the past year. The company is forecast to post a net loss per share of €3.69 next year compared to a net loss per share of €4.15 last year.Reported Earnings • Nov 03Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €284.5m (up 20% from 3Q 2021). Net loss: €20.1m (loss widened 37% from 3Q 2021). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Consumer Retailing industry in Europe.Price Target Changed • Oct 27Price target decreased to €98.79Down from €115, the current price target is an average from 14 analysts. New target price is 126% above last closing price of €43.64. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €3.72 next year compared to a net loss per share of €4.15 last year.Recent Insider Transactions • Aug 28Co-Founder recently sold €972k worth of stockOn the 23rd of August, Stephan Weber sold around 15k shares on-market at roughly €67.03 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.5m. Stephan has been a seller over the last 12 months, reducing personal holdings by €1.9m.Breakeven Date Change • Aug 06No longer forecast to breakevenThe 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.03m in 2024. New consensus forecast suggests the company will make a loss of €2.04m in 2024.Reported Earnings • Aug 05Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €287.2m (up 15% from 2Q 2021). Net loss: €24.8m (loss widened 122% from 2Q 2021). Over the next year, revenue is forecast to grow 26%, compared to a 8.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.Recent Insider Transactions • Jun 19COO & Member of the Managing Board recently sold €1.5m worth of stockOn the 15th of June, Theresa Holler sold around 18k shares on-market at roughly €82.68 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.1m more than they bought in the last 12 months.Recent Insider Transactions • Jun 10Co-Founder recently sold €953k worth of stockOn the 2nd of June, Stephan Weber sold around 10k shares on-market at roughly €95.33 per share. This was the largest sale by an insider in the last 3 months. This was Stephan's only on-market trade for the last 12 months.Breakeven Date Change • May 09No longer forecast to breakevenThe 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024.Reported Earnings • May 08First quarter 2022 earnings: Revenues in line with analyst expectationsFirst quarter 2022 results: Revenue: €304.8m (up 7.3% from 1Q 2021). Net loss: €22.9m (loss widened 296% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 25%, compared to a 7.6% growth forecast for the industry in Germany.Breakeven Date Change • Apr 22No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.93m in 2024.Breakeven Date Change • Apr 09No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €9.14m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024.Recent Insider Transactions • Mar 10Co-Founder recently sold €916k worth of stockOn the 4th of March, Marc Fischer sold around 13k shares on-market at roughly €73.30 per share. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months.Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2024The 13 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 99% per year to 2023. The company is expected to make a profit of €12.5m in 2024. Average annual earnings growth of 85% is required to achieve expected profit on schedule.Reported Earnings • Mar 04Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €1.06b (up 9.5% from FY 2020). Net loss: €74.2m (loss widened 342% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 8.3% growth forecast for the retail industry in Germany.Price Target Changed • Mar 04Price target decreased to €150Down from €163, the current price target is an average from 13 analysts. New target price is 93% above last closing price of €77.95. Stock is down 56% over the past year.Breakeven Date Change • Mar 03Forecast breakeven date pushed back to 2024The 6 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of €33.7m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Reported Earnings • Nov 03Third quarter 2021 earnings releasedThe company reported a poor third quarter result with increased losses and weaker control over costs, although revenues were flat. Third quarter 2021 results: Revenue: €237.9m (flat on 3Q 2020). Net loss: €14.7m (loss widened 240% from 3Q 2020).Breakeven Date Change • Aug 10Forecast breakeven pushed back to 2023The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 68% per year to 2022. The company is expected to make a profit of €24.7m in 2023. Average annual earnings growth of 121% is required to achieve expected profit on schedule.Reported Earnings • Aug 08Second quarter 2021 earnings releasedThe company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €250.4m (up 7.6% from 2Q 2020). Net loss: €11.2m (loss widened €11.0m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Jul 15Price target decreased to €202Down from €221, the current price target is an average from 9 analysts. New target price is 52% above last closing price of €133. Stock is up 9.6% over the past year.Breakeven Date Change • Jun 16Forecast breakeven pushed back to 2022The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 98% to 2021. The company is expected to make a profit of €17.4m in 2022. Average annual earnings growth of 102% is required to achieve expected profit on schedule.Reported Earnings • May 08First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: €284.1m (up 22% from 1Q 2020). Net loss: €5.79m (loss widened 17% from 1Q 2020).Executive Departure • Apr 30Chairman of the Supervisory Board Jan Pyttel has left the companyOn the 21st of April, Jan Pyttel's tenure in the role of Chairman of the Supervisory Board ended. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months.Recent Insider Transactions • Mar 14Chairman of the Managing Board & CEO recently bought €96k worth of stockOn the 8th of March, Stefan Feltens bought around 550 shares on-market at roughly €175 per share. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.Reported Earnings • Mar 05Full year 2020 earnings released: €1.17 loss per share (vs €2.78 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €968.1m (up 38% from FY 2019). Net loss: €16.8m (loss narrowed 54% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Mar 05Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 0.2%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Over the next year, revenue is forecast to grow 23%, compared to a 54% growth forecast for the Online Retail industry in Germany.Is New 90 Day High Low • Feb 03New 90-day high: €210The company is up 29% from its price of €162 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 25% over the same period.Is New 90 Day High Low • Jan 13New 90-day high: €165The company is up 4.0% from its price of €159 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 21% over the same period.Analyst Estimate Surprise Post Earnings • Nov 20Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 26%, compared to a 46% growth forecast for the Online Retail industry in Germany.Analyst Estimate Surprise Post Earnings • Nov 09Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 25%, compared to a 47% growth forecast for the Online Retail industry in Germany.Is New 90 Day High Low • Nov 08New 90-day high: €164The company is up 20% from its price of €137 on 10 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.이익 및 매출 성장 예측DB:RDC - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20284,0944969127712/31/20273,705133889812/31/20263,339-1925983/31/20263,073-37-10217N/A12/31/20252,941-38-8831N/A9/30/20252,821-35-6233N/A6/30/20252,676-35-3644N/A3/31/20252,528-48-1538N/A12/31/20242,371-45-2022N/A9/30/20242,227-25-1131N/A6/30/20242,128-9-833N/A3/31/20241,987-10038N/A12/31/20231,799-122361N/A9/30/20231,595-16-240N/A6/30/20231,404-45-1333N/A3/31/20231,272-65-59-9N/A12/31/20221,204-78-83-29N/A9/30/20221,165-110-68-16N/A6/30/20221,118-105-481N/A3/31/20221,081-91-406N/A12/31/20211,060-74-3212N/A9/30/20211,037-39-1435N/A6/30/20211,038-29-2827N/A3/31/20211,020-18-1735N/A12/31/2020968-17-3618N/A9/30/2020895-15-56-19N/A6/30/2020827-20-43-19N/A3/31/2020758-27-38-16N/A12/31/2019701-36N/A-31N/A9/30/2019660-41N/A-11N/A6/30/2019621-40N/A-10N/A3/31/2019584-40N/A-26N/A12/31/2018540-34N/A-15N/A9/30/2018481-31N/A-31N/A6/30/2018415-28N/A-24N/A3/31/2018351-24N/A-17N/A12/31/2017284-21N/A-23N/A9/30/2017244-22N/A-11N/A6/30/2017222-20N/A-16N/A3/31/2017200-20N/A-14N/A12/31/2016177-18N/A-17N/A9/30/2016159-13N/A-5N/A6/30/2016147-13N/A-5N/A3/31/2016136-12N/A-7N/A12/31/2015126-11N/A-9N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: RDC 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: RDC (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: RDC 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: RDC 의 수익(연간 10.5%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: RDC 의 수익(연간 10.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: RDC의 자본 수익률은 3년 후 12.5%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YConsumer-retailing 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 11:08종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Redcare Pharmacy NV는 24명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gerhard SchwarzBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchSarah RobertsBarclays21명의 분석가 더 보기
Price Target Changed • Jan 07Price target decreased by 7.5% to €140Down from €151, the current price target is an average from 8 analysts. New target price is 107% above last closing price of €67.40. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €1.18 next year compared to a net loss per share of €2.27 last year.
공시 • Mar 13Redcare Pharmacy NV Provides Earnings Guidance for 2025Redcare Pharmacy NV provided earnings guidance for 2025. The company expects Total sales growth in excess of 25%.
Breakeven Date Change • Dec 30Forecast breakeven date pushed back to 2026The 12 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 40% per year to 2025. The company is expected to make a profit of €55.9m in 2026. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Breakeven Date Change • Oct 28Forecast to breakeven in 2025The 12 analysts covering Redcare Pharmacy expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €10.2m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
공시 • Oct 04Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024Redcare Pharmacy NV revised sales guidance for the full year 2024. The company expected for the full year 2024 that sales will end up slightly higher than predicted at the start of the year, and new guidance is total sales between EUR 2.35 billion and EUR 2.5 billion.
Breakeven Date Change • Mar 07Forecast breakeven date moved forward to 2024The 10 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €7.15m in 2024. Earnings growth of 61% is required to achieve expected profit on schedule.
공시 • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.
공시 • Feb 07Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026
공시 • Jan 28Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft SpecificationsRedcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition.
공시 • Jan 08Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026
Price Target Changed • Jan 07Price target decreased by 7.5% to €140Down from €151, the current price target is an average from 8 analysts. New target price is 107% above last closing price of €67.40. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €1.18 next year compared to a net loss per share of €2.27 last year.
공시 • Nov 12+ 1 more updateRedcare Pharmacy NV Designates Hendrik Krampe as Chief Financial Officer, Effective 1 December 2025Redcare Pharmacy announced that the Supervisory Board has designated Hendrik Krampe as Chief Financial Officer, effective 1 December 2025. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. Hendrik Krampe has twenty years of experience in the financial management of fast growing e-commerce businesses. Since 2014, he worked at Amazon where he held the role of Finance Director of the European marketplace business for the last eight years. From 2004 to 2014, Hendrik was at eBay in Germany as well as in the US in various roles including Finance Director of eBay’s Retail Media business. His broad expertise in efficiently scaling digital businesses, particularly marketplaces and Retail Media, complements Redcare Pharmacy´s strategy and will strengthen its core Rx and OTC business. The planned appointment of Hendrik comes at a time of continued growth momentum following strong third quarter results. It will support the company’s aim to increasingly capture economies of scale and improve profitability.
공시 • Oct 07Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025
공시 • Sep 28Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management BoardRedcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor.
공시 • Mar 19Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025
공시 • Mar 13Redcare Pharmacy NV Provides Earnings Guidance for 2025Redcare Pharmacy NV provided earnings guidance for 2025. The company expects Total sales growth in excess of 25%.
공시 • Mar 11Redcare Pharmacy NV to Report Q1, 2025 Results on May 06, 2025Redcare Pharmacy NV announced that they will report Q1, 2025 results on May 06, 2025
공시 • Jan 09Redcare Pharmacy NV to Report Fiscal Year 2024 Final Results on Mar 11, 2025Redcare Pharmacy NV announced that they will report fiscal year 2024 final results on Mar 11, 2025
Breakeven Date Change • Dec 30Forecast breakeven date pushed back to 2026The 12 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 40% per year to 2025. The company is expected to make a profit of €55.9m in 2026. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Reported Earnings • Nov 10Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €574.5m (up 21% from 3Q 2023). Net loss: €6.91m (down 183% from profit in 3Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe.
Breakeven Date Change • Oct 28Forecast to breakeven in 2025The 12 analysts covering Redcare Pharmacy expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €10.2m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
공시 • Oct 04Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024Redcare Pharmacy NV revised sales guidance for the full year 2024. The company expected for the full year 2024 that sales will end up slightly higher than predicted at the start of the year, and new guidance is total sales between EUR 2.35 billion and EUR 2.5 billion.
Reported Earnings • Jul 31Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €560.7m (up 34% from 2Q 2023). Net loss: €4.27m (loss narrowed 6.4% from 2Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in Europe.
공시 • Jul 30Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year. Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year.
New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding).
Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: €560.2m (up 51% from 1Q 2023). Net loss: €7.81m (loss narrowed 24% from 1Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe.
공시 • Mar 07Redcare Pharmacy NV Announces Management DeparturesThe Supervisory Board of Redcare Pharmacy NV agreed to the early departure request of the Managing Board members Stephan Weber (CCO) and Marc Fischer (CIO) at the Annual General Meeting on 17 April 2024. This decision comes at an ideal time to transition leadership responsibilities approximately one year before the end of their regular terms of office. This succession plan had been carefully developed and is the result of an extensive evaluation and selection process. Both Stephan Weber and Marc Fischer have agreed with the Supervisory Board to serve Redcare Pharmacy in an advisory capacity until October 2026, provided the relevant agenda item is approved by the Annual General Meeting.
New Risk • Mar 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
Breakeven Date Change • Mar 07Forecast breakeven date moved forward to 2024The 10 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €7.15m in 2024. Earnings growth of 61% is required to achieve expected profit on schedule.
공시 • Mar 06+ 2 more updatesRedcare Pharmacy NV to Report Q3, 2024 Results on Nov 05, 2024Redcare Pharmacy NV announced that they will report Q3, 2024 results on Nov 05, 2024
Reported Earnings • Mar 06Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: €0.73 loss per share (improved from €4.32 loss in FY 2022). Revenue: €1.80b (up 49% from FY 2022). Net loss: €12.0m (loss narrowed 85% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.
공시 • Mar 05Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024, at 10:00 Central European Standard Time. Agenda: To consider directorate changes.
Price Target Changed • Jan 09Price target increased by 7.6% to €142Up from €132, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €140. Stock is up 144% over the past year. The company is forecast to post a net loss per share of €0.86 next year compared to a net loss per share of €4.32 last year.
Breakeven Date Change • Nov 10Forecast breakeven date moved forward to 2024The 11 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 76% to 2023. The company is expected to make a profit of €229.6k in 2024. Average annual earnings growth of 64% is required to achieve expected profit on schedule.
Reported Earnings • Oct 31Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €475.5m (up 67% from 3Q 2022). Net income: €8.32m (up €28.4m from 3Q 2022). Profit margin: 1.7% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe.
Recent Insider Transactions • Aug 11CFO & Member of Management Board recently sold €1.0m worth of stockOn the 7th of August, Jasper F. Eenhorst sold around 9k shares on-market at roughly €112 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jasper F. has been a net seller over the last 12 months, reducing personal holdings by €992k.
New Risk • Aug 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Significant insider selling over the past 3 months (€454k sold).
Reported Earnings • Aug 02Second quarter 2023 earnings released: €0.24 loss per share (vs €1.37 loss in 2Q 2022)Second quarter 2023 results: €0.24 loss per share (improved from €1.37 loss in 2Q 2022). Revenue: €419.9m (up 46% from 2Q 2022). Net loss: €4.56m (loss narrowed 82% from 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
New Risk • Jun 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €65m Forecast net loss in 2 years: €3.3m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€3.3m net loss in 2 years). Significant insider selling over the past 3 months (€785k sold).
Price Target Changed • Jun 08Price target increased by 8.1% to €101Up from €93.00, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €96.06. Stock is up 7.1% over the past year. The company is forecast to post a net loss per share of €1.87 next year compared to a net loss per share of €4.32 last year.
Price Target Changed • May 23Price target increased by 7.5% to €99.08Up from €92.17, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €97.98. Stock is up 15% over the past year. The company is forecast to post a net loss per share of €2.97 next year compared to a net loss per share of €4.32 last year.
Recent Insider Transactions • May 12Co-Founder recently sold €454k worth of stockOn the 5th of May, Marc Fischer sold around 5k shares on-market at roughly €90.80 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months.
Breakeven Date Change • May 05Forecast to breakeven in 2025The 9 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €15.8m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: €0.56 loss per share. Revenue: €372.1m (up 22% from 1Q 2022). Net loss: €10.2m (loss narrowed 55% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Consumer Retailing industry in Europe.
Breakeven Date Change • Apr 11Forecast to breakeven in 2025The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.44m in 2025. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Recent Insider Transactions • Apr 05COO & Member of the Managing Board recently sold €331k worth of stockOn the 30th of March, Theresa Holler sold around 4k shares on-market at roughly €78.85 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.4m more than they bought in the last 12 months.
Reported Earnings • Mar 09Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: €4.32 loss per share (further deteriorated from €4.15 loss in FY 2021). Revenue: €1.20b (up 14% from FY 2021). Net loss: €77.6m (loss widened 4.7% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Breakeven Date Change • Mar 08No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €26.3m in 2025. New consensus forecast suggests the company will make a loss of €377.1k in 2025.
Recent Insider Transactions • Jan 31COO & Member of the Managing Board recently sold €149k worth of stockOn the 24th of January, Theresa Holler sold around 2k shares on-market at roughly €64.72 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Theresa has been a net seller over the last 12 months, reducing personal holdings by €260k.
Buying Opportunity • Jan 05Now 22% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be €66.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 40% in 2 years. Earnings is forecast to grow by 78% in the next 2 years.
Price Target Changed • Jan 05Price target decreased to €84.43Down from €92.00, the current price target is an average from 14 analysts. New target price is 63% above last closing price of €51.68. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €4.02 next year compared to a net loss per share of €4.15 last year.
Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €26.3m in 2025. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
Recent Insider Transactions • Dec 22Chairman of the Managing Board & CEO recently bought €85k worth of stockOn the 16th of December, Stefan Feltens bought around 2k shares on-market at roughly €42.58 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.
공시 • Dec 20+ 3 more updatesShop Apotheke Europe N.V. to Report Fiscal Year 2022 Results on Mar 07, 2023Shop Apotheke Europe N.V. announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Mar 07, 2023
Price Target Changed • Nov 10Price target decreased to €91.64Down from €98.79, the current price target is an average from 14 analysts. New target price is 106% above last closing price of €44.43. Stock is down 70% over the past year. The company is forecast to post a net loss per share of €3.69 next year compared to a net loss per share of €4.15 last year.
Reported Earnings • Nov 03Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €284.5m (up 20% from 3Q 2021). Net loss: €20.1m (loss widened 37% from 3Q 2021). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Consumer Retailing industry in Europe.
Price Target Changed • Oct 27Price target decreased to €98.79Down from €115, the current price target is an average from 14 analysts. New target price is 126% above last closing price of €43.64. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €3.72 next year compared to a net loss per share of €4.15 last year.
Recent Insider Transactions • Aug 28Co-Founder recently sold €972k worth of stockOn the 23rd of August, Stephan Weber sold around 15k shares on-market at roughly €67.03 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.5m. Stephan has been a seller over the last 12 months, reducing personal holdings by €1.9m.
Breakeven Date Change • Aug 06No longer forecast to breakevenThe 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.03m in 2024. New consensus forecast suggests the company will make a loss of €2.04m in 2024.
Reported Earnings • Aug 05Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €287.2m (up 15% from 2Q 2021). Net loss: €24.8m (loss widened 122% from 2Q 2021). Over the next year, revenue is forecast to grow 26%, compared to a 8.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.
Recent Insider Transactions • Jun 19COO & Member of the Managing Board recently sold €1.5m worth of stockOn the 15th of June, Theresa Holler sold around 18k shares on-market at roughly €82.68 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.1m more than they bought in the last 12 months.
Recent Insider Transactions • Jun 10Co-Founder recently sold €953k worth of stockOn the 2nd of June, Stephan Weber sold around 10k shares on-market at roughly €95.33 per share. This was the largest sale by an insider in the last 3 months. This was Stephan's only on-market trade for the last 12 months.
Breakeven Date Change • May 09No longer forecast to breakevenThe 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024.
Reported Earnings • May 08First quarter 2022 earnings: Revenues in line with analyst expectationsFirst quarter 2022 results: Revenue: €304.8m (up 7.3% from 1Q 2021). Net loss: €22.9m (loss widened 296% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 25%, compared to a 7.6% growth forecast for the industry in Germany.
Breakeven Date Change • Apr 22No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.93m in 2024.
Breakeven Date Change • Apr 09No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €9.14m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024.
Recent Insider Transactions • Mar 10Co-Founder recently sold €916k worth of stockOn the 4th of March, Marc Fischer sold around 13k shares on-market at roughly €73.30 per share. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months.
Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2024The 13 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 99% per year to 2023. The company is expected to make a profit of €12.5m in 2024. Average annual earnings growth of 85% is required to achieve expected profit on schedule.
Reported Earnings • Mar 04Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €1.06b (up 9.5% from FY 2020). Net loss: €74.2m (loss widened 342% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 8.3% growth forecast for the retail industry in Germany.
Price Target Changed • Mar 04Price target decreased to €150Down from €163, the current price target is an average from 13 analysts. New target price is 93% above last closing price of €77.95. Stock is down 56% over the past year.
Breakeven Date Change • Mar 03Forecast breakeven date pushed back to 2024The 6 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of €33.7m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Reported Earnings • Nov 03Third quarter 2021 earnings releasedThe company reported a poor third quarter result with increased losses and weaker control over costs, although revenues were flat. Third quarter 2021 results: Revenue: €237.9m (flat on 3Q 2020). Net loss: €14.7m (loss widened 240% from 3Q 2020).
Breakeven Date Change • Aug 10Forecast breakeven pushed back to 2023The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 68% per year to 2022. The company is expected to make a profit of €24.7m in 2023. Average annual earnings growth of 121% is required to achieve expected profit on schedule.
Reported Earnings • Aug 08Second quarter 2021 earnings releasedThe company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €250.4m (up 7.6% from 2Q 2020). Net loss: €11.2m (loss widened €11.0m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Jul 15Price target decreased to €202Down from €221, the current price target is an average from 9 analysts. New target price is 52% above last closing price of €133. Stock is up 9.6% over the past year.
Breakeven Date Change • Jun 16Forecast breakeven pushed back to 2022The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 98% to 2021. The company is expected to make a profit of €17.4m in 2022. Average annual earnings growth of 102% is required to achieve expected profit on schedule.
Reported Earnings • May 08First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: €284.1m (up 22% from 1Q 2020). Net loss: €5.79m (loss widened 17% from 1Q 2020).
Executive Departure • Apr 30Chairman of the Supervisory Board Jan Pyttel has left the companyOn the 21st of April, Jan Pyttel's tenure in the role of Chairman of the Supervisory Board ended. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months.
Recent Insider Transactions • Mar 14Chairman of the Managing Board & CEO recently bought €96k worth of stockOn the 8th of March, Stefan Feltens bought around 550 shares on-market at roughly €175 per share. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.
Reported Earnings • Mar 05Full year 2020 earnings released: €1.17 loss per share (vs €2.78 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €968.1m (up 38% from FY 2019). Net loss: €16.8m (loss narrowed 54% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Mar 05Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 0.2%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Over the next year, revenue is forecast to grow 23%, compared to a 54% growth forecast for the Online Retail industry in Germany.
Is New 90 Day High Low • Feb 03New 90-day high: €210The company is up 29% from its price of €162 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 25% over the same period.
Is New 90 Day High Low • Jan 13New 90-day high: €165The company is up 4.0% from its price of €159 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 21% over the same period.
Analyst Estimate Surprise Post Earnings • Nov 20Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 26%, compared to a 46% growth forecast for the Online Retail industry in Germany.
Analyst Estimate Surprise Post Earnings • Nov 09Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 25%, compared to a 47% growth forecast for the Online Retail industry in Germany.
Is New 90 Day High Low • Nov 08New 90-day high: €164The company is up 20% from its price of €137 on 10 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.